KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Income from Continuing Operations: 2012-2025

Historic Income from Continuing Operations for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$447.6 million.

  • Sarepta Therapeutics' Income from Continuing Operations fell 7028.08% to -$447.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$248.7 million, marking a year-over-year decrease of 627.64%. This contributed to the annual value of $235.0 million for FY2024, which is 143.83% up from last year.
  • Sarepta Therapeutics' Income from Continuing Operations amounted to -$447.6 million in Q2 2025, which was down 381.84% from $158.8 million recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' Income from Continuing Operations peaked at $158.8 million during Q4 2024, and registered a low of -$516.8 million during Q1 2023.
  • For the 3-year period, Sarepta Therapeutics' Income from Continuing Operations averaged around -$83.2 million, with its median value being $6.5 million (2024).
  • As far as peak fluctuations go, Sarepta Therapeutics' Income from Continuing Operations skyrocketed by 248.80% in 2024, and later tumbled by 7,028.08% in 2025.
  • Sarepta Therapeutics' Income from Continuing Operations (Quarterly) stood at -$122.0 million in 2021, then grew by 9.94% to -$109.9 million in 2022, then surged by 141.44% to $45.5 million in 2023, then surged by 248.80% to $158.8 million in 2024, then tumbled by 7,028.08% to -$447.6 million in 2025.
  • Its Income from Continuing Operations was -$447.6 million in Q2 2025, compared to $158.8 million in Q4 2024 and $33.6 million in Q3 2024.